The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer
- 10 November 2021
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 39 (1) , 1-11
Abstract
The deregulation of microRNAs (miRs) has been identified in tumor development. Indeed, the restoration of tumor-suppressive miRs has been associated with inhibited tumor development in various cancers. Herein, we aimed to evaluate the impact of combined miR-383-5p restoration, as a tumor-suppressive miR, with taxol therapy in suppressing MDA-MB-231 breast cancer development. MDA-MB-231 cell line was restored with miR-383-5p and treated with paclitaxel both in combined and separate manners. The MTT experiment was carried out to measure the cytotoxicity of the therapeutic approaches on the tumoral cells. Besides, flow cytometry was conducted to assess apoptosis and cell cycle status following the treatments. Furthermore, the expression levels of critical factors contributed to tumor proliferation, migration, apoptosis were investigated via the qRT-PCR and western blotting techniques. The outcomes pointed out that the miR-383-5p might substantially enhance the chemosensitivity of MDA-MB-231 to taxol. Besides, miR-383-5p restoration and the combined therapy of miR-383-5p restoration with paclitaxel could remarkably increase apoptosis, decrease cell viability, arrest the cell cycle, inhibit clonogenicity, suppress tumor migration, suppress the PI3K/Akt signaling pathway, and down-regulate PD-L1 expression of BC cells. The restoration of miR-383-5p can enhance the chemosensitivity of MDA-MB-231 cells to taxol. Despite the anti-tumoral effects of miR-383-5p restoration on MDA-MB-231 breast cancer development, the combined therapy of miR-383-5p restoration with paclitaxel can be more effective in repressing MDA-MB-231 breast cancer development.Keywords
Funding Information
- University of Tabriz (3522)
This publication has 28 references indexed in Scilit:
- The intracellular signalosome of PD-L1 in cancer cellsSignal Transduction and Targeted Therapy, 2018
- miR‐383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1Journal of Cellular Biochemistry, 2018
- Upregulation of microRNA‑383 inhibits the proliferation, migration and invasion of colon cancer cellsOncology Letters, 2017
- A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/AkT/MTOR signaling pathwayOncoTargets and Therapy, 2017
- miR-383 inhibits ovarian cancer cell proliferation, invasion and aerobic glycolysis by targeting LDHANeoplasma, 2017
- miRNA Deregulation in Cancer Cells and the Tumor MicroenvironmentCancer Discovery, 2016
- The role of MicroRNAs in human cancerSignal Transduction and Targeted Therapy, 2016
- Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptorMedical Oncology, 2013
- Effect of PI3K gene silencing on growth, migration and related proteins expression of CD40 signal-mediated gastric cancer cellsMolecular Biology Reports, 2012
- Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9Hepatology Research, 2009